ZenGUARD™ Revolutionizes Air Filtration as Class 1 Medical Device

Zentek Ltd., a leading nanotechnology company specializing in next-gen healthcare solutions, has announced a significant milestone in its commitment to enhanced infection control. The company plans to add its ZenGUARD™ Enhanced Air Filters as a Class 1 medical device under its existing Medical Device Establishment Licence (MDEL). This strategic move positions Zentek to capitalize on the growing demand for effective indoor air quality solutions, particularly in light of ongoing concerns regarding airborne pathogens.

Independent testing has confirmed the remarkable potential of ZenGUARD™ Enhanced Air Filters, demonstrating a 66% improvement in viral filtration efficiency compared to untreated filters. The filters have maintained this high performance over six months, with minimal changes in pressure drop, ensuring optimal energy efficiency. A study by ParticleOne further validated the product's effectiveness in reducing viral pathogens and potential cost savings through reduced absenteeism.



To qualify the filters as a medical device under MDEL and ISO 13485:2016 compliance, Zentek must complete additional testing and documentation. However, the company anticipates that this process will be less resource-intensive than previous pathways, reflecting its extensive experience in regulatory hurdles. Zentek's commitment to quality and regulatory adherence, as evidenced by its ISO 13485:2016 certification, further bolsters customer trust and market acceptance.

This announcement comes as Zentek continues to expand its portfolio of innovative healthcare solutions, including ZenGUARD™ Surgical Masks and other PPE products. The company's intellectual property development and commercialization focus enable it to create significant value through next-generation solutions, addressing critical public health needs.



Zentek's addition of ZenGUARD™ Enhanced Air Filters as a Class 1 medical device under its MDEL highlights a critical growth opportunity within the company and the broader healthcare market. The rigorous testing demonstrating superior viral filtration efficiency and minimal pressure drop changes over extended usage positions ZenGUARD™ filters as a competitive edge in the market for air filtration systems. Moreover, potential cost savings for organizations through reduced absenteeism attributed to poor indoor air quality enhance the product's appeal from both health and economic perspectives.

Investors should closely monitor Zentek's progress as it continues to execute its strategy in the dynamic market landscape. With the increasing focus on health and safety in public spaces, Zentek's approach aligns well with sector trends, suggesting strong potential for revenue growth and market expansion.

In conclusion, Zentek's ZenGUARD™ Enhanced Air Filters represent a compelling investment opportunity in the nexus of healthcare technology and public health safety. As the company mobilizes its strategy to address critical public health needs, investors can benefit from the ongoing market growth and enhanced safety measures that ZenGUARD™ filters offer.